Intensity Therapeutics (NASDAQ:INTS) Price Target Raised to $7.00

by · The Cerbat Gem

Intensity Therapeutics (NASDAQ:INTS – Free Report) had its price objective lifted by HC Wainwright from $5.00 to $7.00 in a report published on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Intensity Therapeutics’ Q3 2026 earnings at ($1.11) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.88) EPS, Q1 2027 earnings at ($0.21) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.77) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.54) EPS.

A number of other research firms have also recently issued reports on INTS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

View Our Latest Stock Analysis on Intensity Therapeutics

Intensity Therapeutics Trading Up 16.2%

Shares of NASDAQ INTS opened at $4.88 on Tuesday. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a twelve month low of $3.51 and a twelve month high of $43.50. The company’s fifty day moving average is $4.30 and its 200-day moving average is $5.37. The stock has a market cap of $15.91 million, a price-to-earnings ratio of -1.37 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Equities research analysts predict that Intensity Therapeutics will post -2.64 EPS for the current year.

Institutional Trading of Intensity Therapeutics

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $26,000. Corient Private Wealth LLC acquired a new stake in Intensity Therapeutics during the 4th quarter valued at $41,000. State Street Corp lifted its holdings in Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares during the last quarter. Legacy Advisors LLC bought a new position in Intensity Therapeutics during the fourth quarter worth $63,000. Finally, Mesirow Financial Investment Management Inc. boosted its position in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after purchasing an additional 51,000 shares during the period. 3.74% of the stock is owned by institutional investors and hedge funds.

Key Intensity Therapeutics News

Here are the key news stories impacting Intensity Therapeutics this week:

  • Positive Sentiment: HC Wainwright maintained a Buy rating and a $7.00 price target for Intensity Therapeutics, supporting investor confidence in the biotechnology company’s longer-term outlook. Intensity Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
  • Positive Sentiment: HC Wainwright projects that annual losses will narrow from an estimated $1.88 per share in fiscal 2026 to $0.92 in 2027, $0.77 in 2028 and $0.54 in 2030. The improving loss trajectory may be viewed as a sign of potential progress toward profitability, though the forecasts remain negative through 2030.
  • Neutral Sentiment: HC Wainwright’s estimates include losses of $1.11 per share in the third quarter of 2026 and $0.20 per share in the fourth quarter, with 2027 quarterly losses ranging from $0.21 to $0.26 per share. These forecasts provide updated expectations but do not indicate near-term profitability.
  • Negative Sentiment: Brookline Capital Markets cut its third-quarter EPS estimate for Intensity Therapeutics, creating a modest negative signal about near-term results. The company’s latest reported quarter also missed consensus EPS estimates, underscoring ongoing execution and funding risks for the small-cap biotechnology firm. Q3 EPS Estimates for INTS Cut by Brookline Capital Markets

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.

See Also